메뉴 건너뛰기




Volumn 32, Issue 19, 2014, Pages 2241-2250

Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial

Author keywords

Active immunotherapy; Angiogenesis; Cancer; Clinical trial; Vaccine; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CIGB 247; GAMMA INTERFERON ANTIBODY; IMMUNOGLOBULIN G; OUTER MEMBRANE PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN ANTIBODY;

EID: 84897107462     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.102     Document Type: Article
Times cited : (44)

References (62)
  • 1
    • 33947732977 scopus 로고    scopus 로고
    • Angiogenesis: an organizing principle for drug discovery?
    • Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6(April (4)):273-286.
    • (2007) Nat Rev Drug Discov , vol.6 , Issue.APRIL 4 , pp. 273-286
    • Folkman, J.1
  • 2
    • 85013312416 scopus 로고
    • Tumor angiogenesis: therapeutic implications
    • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(November (21)):1182-1186.
    • (1971) N Engl J Med , vol.285 , Issue.NOVEMBER 21 , pp. 1182-1186
    • Folkman, J.1
  • 3
    • 0037376877 scopus 로고    scopus 로고
    • Angiogenesis and apoptosis
    • Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003, 13(April (2)):159-167.
    • (2003) Semin Cancer Biol , vol.13 , Issue.APRIL 2 , pp. 159-167
    • Folkman, J.1
  • 4
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(June (23)):2335-2342.
    • (2004) N Engl J Med , vol.350 , Issue.JUNE 23 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3    Cartwright, T.4    Hainsworth, J.5    Heim, W.6
  • 5
    • 33646448005 scopus 로고    scopus 로고
    • Sunitinib malate for the treatment of solid tumours: a review of current clinical data
    • Motzer R.J., Hoosen S., Bello C.L., Christensen J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006, 15(May (5)):553-561.
    • (2006) Expert Opin Investig Drugs , vol.15 , Issue.MAY 5 , pp. 553-561
    • Motzer, R.J.1    Hoosen, S.2    Bello, C.L.3    Christensen, J.G.4
  • 6
    • 79952543555 scopus 로고    scopus 로고
    • Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma
    • Keisner S.V., Shah S.R. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011, 71(March (4)):443-454.
    • (2011) Drugs , vol.71 , Issue.MARCH 4 , pp. 443-454
    • Keisner, S.V.1    Shah, S.R.2
  • 8
    • 84860389208 scopus 로고    scopus 로고
    • Vandetanib (ZD6474) in the treatment of medullary thyroid cancer
    • Deshpande H., Roman S., Thumar J., Sosa J.A. Vandetanib (ZD6474) in the treatment of medullary thyroid cancer. Clin Med Insights Oncol 2011, July (5):213-221. 10.4137/CMO.S6197.213-21.
    • (2011) Clin Med Insights Oncol , vol.JULY , Issue.5 , pp. 213-221
    • Deshpande, H.1    Roman, S.2    Thumar, J.3    Sosa, J.A.4
  • 9
    • 84865253075 scopus 로고    scopus 로고
    • Concise drug review: pazopanib and axitinib
    • van Geel R.M., Beijnen J.H., Schellens J.H. Concise drug review: pazopanib and axitinib. Oncologist 2012, 17(August (8)):1081-1089.
    • (2012) Oncologist , vol.17 , Issue.AUGUST 8 , pp. 1081-1089
    • van Geel, R.M.1    Beijnen, J.H.2    Schellens, J.H.3
  • 10
    • 84863691378 scopus 로고    scopus 로고
    • Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
    • Singh M., Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol 2012, 30(July (7)):648-657.
    • (2012) Nat Biotechnol , vol.30 , Issue.JULY 7 , pp. 648-657
    • Singh, M.1    Ferrara, N.2
  • 11
    • 79955641941 scopus 로고    scopus 로고
    • Vaccines targeting the neovasculature of tumors
    • Matejuk A., Leng Q., Chou S.T., Mixson A.J. Vaccines targeting the neovasculature of tumors. Vasc Cell 2011, 3(1):7.
    • (2011) Vasc Cell , vol.3 , Issue.1 , pp. 7
    • Matejuk, A.1    Leng, Q.2    Chou, S.T.3    Mixson, A.J.4
  • 12
    • 33646174504 scopus 로고    scopus 로고
    • Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy
    • Okaji Y., Tsuno N.H., Saito S., Yoneyama S., Tanaka M., Nagawa H., et al. Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006, 32(May (4)):363-370.
    • (2006) Eur J Surg Oncol , vol.32 , Issue.MAY 4 , pp. 363-370
    • Okaji, Y.1    Tsuno, N.H.2    Saito, S.3    Yoneyama, S.4    Tanaka, M.5    Nagawa, H.6
  • 13
    • 44249087196 scopus 로고    scopus 로고
    • Anti-angiogenic active immunotherapy: a new approach to cancer treatment
    • Pan J., Jin P., Yan J., Kabelitz D. Anti-angiogenic active immunotherapy: a new approach to cancer treatment. Cancer Immunol Immunother 2008, 57(August (8)):1105-1114.
    • (2008) Cancer Immunol Immunother , vol.57 , Issue.AUGUST 8 , pp. 1105-1114
    • Pan, J.1    Jin, P.2    Yan, J.3    Kabelitz, D.4
  • 14
  • 15
    • 0035949593 scopus 로고    scopus 로고
    • Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen
    • Wei Y.Q., Huang M.J., Yang L., Zhao X., Tian L., Lu Y., et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci U S A 2001, 98(September (20)):11545-11550.
    • (2001) Proc Natl Acad Sci U S A , vol.98 , Issue.SEPTEMBER 20 , pp. 11545-11550
    • Wei, Y.Q.1    Huang, M.J.2    Yang, L.3    Zhao, X.4    Tian, L.5    Lu, Y.6
  • 16
    • 38049071219 scopus 로고    scopus 로고
    • Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice
    • Li X.H., Tang L., Liu D., Sun H.M., Zhou C.C., Tan L.S., et al. Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice. Ai Zheng 2006, October (25)(10):1221-1226.
    • (2006) Ai Zheng , Issue.10 OCTOBER 25 , pp. 1221-1226
    • Li, X.H.1    Tang, L.2    Liu, D.3    Sun, H.M.4    Zhou, C.C.5    Tan, L.S.6
  • 17
    • 33847673267 scopus 로고    scopus 로고
    • Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice
    • Bequet-Romero M., Ayala M., Acevedo B.E., Rodriguez E.G., Ocejo O.L., Torrens I., et al. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis 2007, 10(1):23-34.
    • (2007) Angiogenesis , vol.10 , Issue.1 , pp. 23-34
    • Bequet-Romero, M.1    Ayala, M.2    Acevedo, B.E.3    Rodriguez, E.G.4    Ocejo, O.L.5    Torrens, I.6
  • 18
    • 33847326301 scopus 로고    scopus 로고
    • VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases
    • Rad F.H., Le B.H., Paturance S., Larcier P., Genne P., Ryffel B., et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A 2007, 104(February (8)):2837-2842.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , Issue.FEBRUARY 8 , pp. 2837-2842
    • Rad, F.H.1    Le, B.H.2    Paturance, S.3    Larcier, P.4    Genne, P.5    Ryffel, B.6
  • 19
    • 34248592407 scopus 로고    scopus 로고
    • Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma
    • Kamstock D., Elmslie R., Thamm D., Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 2007, 56(August (8)):1299-1309.
    • (2007) Cancer Immunol Immunother , vol.56 , Issue.AUGUST 8 , pp. 1299-1309
    • Kamstock, D.1    Elmslie, R.2    Thamm, D.3    Dow, S.4
  • 20
    • 58149351409 scopus 로고    scopus 로고
    • Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants
    • Morera Y., Bequet-Romero M., Ayala M., Lamdan H., Agger E.M., Andersen P., et al. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 2008, 11(4):381-393.
    • (2008) Angiogenesis , vol.11 , Issue.4 , pp. 381-393
    • Morera, Y.1    Bequet-Romero, M.2    Ayala, M.3    Lamdan, H.4    Agger, E.M.5    Andersen, P.6
  • 21
    • 84857457850 scopus 로고    scopus 로고
    • CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors
    • Bequet-Romero M., Morera Y., Ayala-Avila M., Ancizar J., Soria Y., Blanco A., et al. CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors. Vaccine 2012, 30(February (10)):1790-1799.
    • (2012) Vaccine , vol.30 , Issue.FEBRUARY 10 , pp. 1790-1799
    • Bequet-Romero, M.1    Morera, Y.2    Ayala-Avila, M.3    Ancizar, J.4    Soria, Y.5    Blanco, A.6
  • 22
    • 77950628629 scopus 로고    scopus 로고
    • Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates
    • Morera Y., Bequet-Romero M., Ayala M., Velazco J.C., Perez P.P., Alba J.S., et al. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine 2010, 28(April (19)):3453-3461.
    • (2010) Vaccine , vol.28 , Issue.APRIL 19 , pp. 3453-3461
    • Morera, Y.1    Bequet-Romero, M.2    Ayala, M.3    Velazco, J.C.4    Perez, P.P.5    Alba, J.S.6
  • 23
    • 84355161453 scopus 로고    scopus 로고
    • Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates
    • Morera Y., Bequet-Romero M., Ayala M., Perez P.P., Castro J., Sanchez J., et al. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine 2012, 30(January (2)):368-377.
    • (2012) Vaccine , vol.30 , Issue.JANUARY 2 , pp. 368-377
    • Morera, Y.1    Bequet-Romero, M.2    Ayala, M.3    Perez, P.P.4    Castro, J.5    Sanchez, J.6
  • 24
    • 70350002279 scopus 로고    scopus 로고
    • Adverse effects of anticancer agents that target the VEGF pathway
    • Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6(August (8)):465-477.
    • (2009) Nat Rev Clin Oncol , vol.6 , Issue.AUGUST 8 , pp. 465-477
    • Chen, H.X.1    Cleck, J.N.2
  • 25
    • 77956072936 scopus 로고    scopus 로고
    • Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study
    • Kozloff M.F., Berlin J., Flynn P.J., Kabbinavar F., Ashby M., Dong W., et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010, 78(5-6):329-339.
    • (2010) Oncology , vol.78 , Issue.5-6 , pp. 329-339
    • Kozloff, M.F.1    Berlin, J.2    Flynn, P.J.3    Kabbinavar, F.4    Ashby, M.5    Dong, W.6
  • 26
    • 84867577603 scopus 로고    scopus 로고
    • The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801)
    • Nakayama G., Uehara K., Ishigure K., Yokoyama H., Ishiyama A., Eguchi T., et al. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801). Cancer Chemother Pharmacol 2012, 70(October (4)):575-581.
    • (2012) Cancer Chemother Pharmacol , vol.70 , Issue.OCTOBER 4 , pp. 575-581
    • Nakayama, G.1    Uehara, K.2    Ishigure, K.3    Yokoyama, H.4    Ishiyama, A.5    Eguchi, T.6
  • 27
    • 84873619713 scopus 로고    scopus 로고
    • Targeted anti-vascular therapies for ovarian cancer: current evidence
    • Hall M., Gourley C., McNeish I., Ledermann J., Gore M., Jayson G., et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 2013, 108(February (2)):250-258.
    • (2013) Br J Cancer , vol.108 , Issue.FEBRUARY 2 , pp. 250-258
    • Hall, M.1    Gourley, C.2    Mcneish, I.3    Ledermann, J.4    Gore, M.5    Jayson, G.6
  • 28
    • 38749147680 scopus 로고    scopus 로고
    • Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy
    • Okaji Y., Tsuno N.H., Tanaka M., Yoneyama S., Matsuhashi M., Kitayama J., et al. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer 2008, 44(February (3)):383-390.
    • (2008) Eur J Cancer , vol.44 , Issue.FEBRUARY 3 , pp. 383-390
    • Okaji, Y.1    Tsuno, N.H.2    Tanaka, M.3    Yoneyama, S.4    Matsuhashi, M.5    Kitayama, J.6
  • 29
    • 78651391336 scopus 로고    scopus 로고
    • Gastrointestinal bleeding during antiangiogenic peptide vaccination in combination with gembcitabine for advanced pancreatic cancer
    • Nagayama H., Kazufumi M., Nayuki I., Hideki O., Naoyuki T., Takashi N. Gastrointestinal bleeding during antiangiogenic peptide vaccination in combination with gembcitabine for advanced pancreatic cancer. Clin J Gastroenterol 2010, 706. 10.1007/s12328-010-0178-5.
    • (2010) Clin J Gastroenterol , vol.706
    • Nagayama, H.1    Kazufumi, M.2    Nayuki, I.3    Hideki, O.4    Naoyuki, T.5    Takashi, N.6
  • 30
    • 84876420644 scopus 로고    scopus 로고
    • Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
    • Yoshimura K., Minami T., Nozawa M., Uemura H. Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Br J Cancer 2013, 108(April (6)):1260-1266.
    • (2013) Br J Cancer , vol.108 , Issue.APRIL 6 , pp. 1260-1266
    • Yoshimura, K.1    Minami, T.2    Nozawa, M.3    Uemura, H.4
  • 31
    • 84865204316 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-receptor 2 in patients with stage IV and locally advanced pancreatic cancer
    • Niethammer A.G., Lubenau H., Mikus G., Knebel P., Hohmann N., Leowardi C., et al. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 2012, 12(August):361. 10.1186/1471-2407-12-361.
    • (2012) BMC Cancer , vol.12 , Issue.AUGUST , pp. 361
    • Niethammer, A.G.1    Lubenau, H.2    Mikus, G.3    Knebel, P.4    Hohmann, N.5    Leowardi, C.6
  • 32
    • 75649099783 scopus 로고    scopus 로고
    • Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
    • Miyazawa M., Ohsawa R., Tsunoda T., Hirono S., Kawai M., Tani M., et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010, 101(February (2)):433-439.
    • (2010) Cancer Sci , vol.101 , Issue.FEBRUARY 2 , pp. 433-439
    • Miyazawa, M.1    Ohsawa, R.2    Tsunoda, T.3    Hirono, S.4    Kawai, M.5    Tani, M.6
  • 33
    • 30444446808 scopus 로고    scopus 로고
    • Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells
    • de L.J., Fernandez A., Mesa C., Clavel M., Fernandez L.E. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006, 55(April (4)):443-450.
    • (2006) Cancer Immunol Immunother , vol.55 , Issue.APRIL 4 , pp. 443-450
    • de, L.J.1    Fernandez, A.2    Mesa, C.3    Clavel, M.4    Fernandez, L.E.5
  • 34
    • 79251551682 scopus 로고    scopus 로고
    • Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant
    • Fernandez A., Mesa C., Marigo I., Dolcetti L., Clavell M., Oliver L., et al. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol 2011, 186(January (1)):264-274.
    • (2011) J Immunol , vol.186 , Issue.JANUARY 1 , pp. 264-274
    • Fernandez, A.1    Mesa, C.2    Marigo, I.3    Dolcetti, L.4    Clavell, M.5    Oliver, L.6
  • 35
    • 3843071048 scopus 로고    scopus 로고
    • Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation
    • AUGUST 23-24
    • Mesa C., de L.J., Rigley K., Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 2004, 22(August (23-24)):3045-3052.
    • (2004) Vaccine , vol.22 , pp. 3045-3052
    • Mesa, C.1    de, L.J.2    Rigley, K.3    Fernandez, L.E.4
  • 36
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    • Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(January (2)):228-247.
    • (2009) Eur J Cancer , vol.45 , Issue.JANUARY 2 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3    Schwartz, L.H.4    Sargent, D.5    Ford, R.6
  • 38
    • 80555129210 scopus 로고    scopus 로고
    • Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories
    • Moodie Z., Price L., Janetzki S., Britten C.M. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol 2012, 792:185-196.
    • (2012) Methods Mol Biol , vol.792 , pp. 185-196
    • Moodie, Z.1    Price, L.2    Janetzki, S.3    Britten, C.M.4
  • 39
    • 79953750263 scopus 로고    scopus 로고
    • Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond
    • Britten C.M., Janetzki S., van der Burg S.H., Huber C., Kalos M., Levitsky H.I., et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 2011, 60(January (1)):15-22.
    • (2011) Cancer Immunol Immunother , vol.60 , Issue.JANUARY 1 , pp. 15-22
    • Britten, C.M.1    Janetzki, S.2    van der Burg, S.H.3    Huber, C.4    Kalos, M.5    Levitsky, H.I.6
  • 40
    • 0034212632 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen
    • Adams J., Carder P.J., Downey S., Forbes M.A., MacLennan K., Allgar V., et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000, 60(June (11)):2898-2905.
    • (2000) Cancer Res , vol.60 , Issue.JUNE 11 , pp. 2898-2905
    • Adams, J.1    Carder, P.J.2    Downey, S.3    Forbes, M.A.4    Maclennan, K.5    Allgar, V.6
  • 41
    • 0035990391 scopus 로고    scopus 로고
    • Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study
    • Bada A., Casaco P.A., Arteaga M., Martinez J., Leon A., Santana E., et al. Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study. Hum Exp Toxicol 2002, 21(May (5)):263-267.
    • (2002) Hum Exp Toxicol , vol.21 , Issue.MAY 5 , pp. 263-267
    • Bada, A.1    Casaco, P.A.2    Arteaga, M.3    Martinez, J.4    Leon, A.5    Santana, E.6
  • 42
    • 7444262837 scopus 로고    scopus 로고
    • Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity
    • Guthmann M.D., Bitton R.J., Carnero A.J., Gabri M.R., Cinat G., Koliren L., et al. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother 2004, 27(November (6)):442-451.
    • (2004) J Immunother , vol.27 , Issue.NOVEMBER 6 , pp. 442-451
    • Guthmann, M.D.1    Bitton, R.J.2    Carnero, A.J.3    Gabri, M.R.4    Cinat, G.5    Koliren, L.6
  • 43
    • 84897114321 scopus 로고    scopus 로고
    • An alternative clinical trial for early cancer vaccine development to phase 3+3 design
    • Suppl. 2578
    • Gammoh E., Rahma O.E., Simon R., Khleif S. An alternative clinical trial for early cancer vaccine development to phase 3+3 design. J Clin Oncol (Meeting Abs) 2012, 30(15). Suppl. 2578.
    • (2012) J Clin Oncol (Meeting Abs) , vol.30 , Issue.15
    • Gammoh, E.1    Rahma, O.E.2    Simon, R.3    Khleif, S.4
  • 44
    • 0141891468 scopus 로고    scopus 로고
    • Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells
    • Rentzsch C., Kayser S., Stumm S., Watermann I., Walter S., Stevanovic S., et al. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res 2003, 9(October (12)):4376-4386.
    • (2003) Clin Cancer Res , vol.9 , Issue.OCTOBER 12 , pp. 4376-4386
    • Rentzsch, C.1    Kayser, S.2    Stumm, S.3    Watermann, I.4    Walter, S.5    Stevanovic, S.6
  • 46
    • 78349289653 scopus 로고    scopus 로고
    • The SSX family of cancer-testis antigens as target proteins for tumor therapy
    • [Epub@2010 Oct 11: 150591]
    • Smith H.A., McNeel D.G. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol 2010, 2010:150591. [Epub@2010 Oct 11: 150591]. 10.1155/2010/150591.
    • (2010) Clin Dev Immunol , vol.2010 , pp. 150591
    • Smith, H.A.1    Mcneel, D.G.2
  • 47
    • 35649005398 scopus 로고    scopus 로고
    • Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
    • Morse M.A., Hobeika A., Osada T., Niedzwiecki D., Marcom P.K., Blackwell K.L., et al. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med 2007, 5(September):42.
    • (2007) J Transl Med , vol.5 , Issue.SEPTEMBER , pp. 42
    • Morse, M.A.1    Hobeika, A.2    Osada, T.3    Niedzwiecki, D.4    Marcom, P.K.5    Blackwell, K.L.6
  • 48
    • 84860188105 scopus 로고    scopus 로고
    • Therapeutic cancer vaccines: current status and moving forward
    • Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012, 104(April (8)):599-613.
    • (2012) J Natl Cancer Inst , vol.104 , Issue.APRIL 8 , pp. 599-613
    • Schlom, J.1
  • 49
    • 34347381738 scopus 로고    scopus 로고
    • Cancer vaccines: a promising cancer therapy against all odds
    • Silk A.W., Finn O.J. Cancer vaccines: a promising cancer therapy against all odds. Fut Oncol 2007, 3(June (3)):299-306.
    • (2007) Fut Oncol , vol.3 , Issue.JUNE 3 , pp. 299-306
    • Silk, A.W.1    Finn, O.J.2
  • 50
    • 34447136106 scopus 로고    scopus 로고
    • Cancer vaccines: moving beyond current paradigms
    • Schlom J., Arlen P.M., Gulley J.L. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007, 13(July (13)):3776-3782.
    • (2007) Clin Cancer Res , vol.13 , Issue.JULY 13 , pp. 3776-3782
    • Schlom, J.1    Arlen, P.M.2    Gulley, J.L.3
  • 51
    • 46949084994 scopus 로고    scopus 로고
    • Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
    • Sessa C., Guibal A., Del C.G., Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. Nat Clin Pract Oncol 2008, 5(July (7)):378-391.
    • (2008) Nat Clin Pract Oncol , vol.5 , Issue.JULY 7 , pp. 378-391
    • Sessa, C.1    Guibal, A.2    Del, C.G.3    Ruegg, C.4
  • 53
    • 33845247353 scopus 로고    scopus 로고
    • Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
    • Bernhardt S.L., Gjertsen M.K., Trachsel S., Moller M., Eriksen J.A., Meo M., et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006, 95(December (11)):1474-1482.
    • (2006) Br J Cancer , vol.95 , Issue.DECEMBER 11 , pp. 1474-1482
    • Bernhardt, S.L.1    Gjertsen, M.K.2    Trachsel, S.3    Moller, M.4    Eriksen, J.A.5    Meo, M.6
  • 54
    • 49149117772 scopus 로고    scopus 로고
    • Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine
    • Holmes J.P., Benavides L.C., Gates J.D., Carmichael M.G., Hueman M.T., Mittendorf E.A., et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008, 26(July (20)):3426-3433.
    • (2008) J Clin Oncol , vol.26 , Issue.JULY 20 , pp. 3426-3433
    • Holmes, J.P.1    Benavides, L.C.2    Gates, J.D.3    Carmichael, M.G.4    Hueman, M.T.5    Mittendorf, E.A.6
  • 55
    • 3042745485 scopus 로고    scopus 로고
    • Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine
    • Disis M.L., Schiffman K., Guthrie K., Salazar L.G., Knutson K.L., Goodell V., et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004, 22(May (10)):1916-1925.
    • (2004) J Clin Oncol , vol.22 , Issue.MAY 10 , pp. 1916-1925
    • Disis, M.L.1    Schiffman, K.2    Guthrie, K.3    Salazar, L.G.4    Knutson, K.L.5    Goodell, V.6
  • 56
    • 56749170720 scopus 로고    scopus 로고
    • Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
    • Perales M.A., Yuan J., Powel S., Gallardo H.F., Rasalan T.S., Gonzalez C., et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 2008, 16(December (12)):2022-2029.
    • (2008) Mol Ther , vol.16 , Issue.DECEMBER 12 , pp. 2022-2029
    • Perales, M.A.1    Yuan, J.2    Powel, S.3    Gallardo, H.F.4    Rasalan, T.S.5    Gonzalez, C.6
  • 57
    • 0033153564 scopus 로고    scopus 로고
    • Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial
    • van Driel W.J., Ressing M.E., Kenter G.G., Brandt R.M., Krul E.J., van Rossum A.B., et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999, 35(June (6)):946-952.
    • (1999) Eur J Cancer , vol.35 , Issue.JUNE 6 , pp. 946-952
    • van Driel, W.J.1    Ressing, M.E.2    Kenter, G.G.3    Brandt, R.M.4    Krul, E.J.5    van Rossum, A.B.6
  • 58
    • 84867811471 scopus 로고    scopus 로고
    • First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
    • Berinstein N.L., Karkada M., Morse M.A., Nemunaitis J.J., Chatta G., Kaufman H., et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med 2012, 10:156.
    • (2012) J Transl Med , vol.10 , pp. 156
    • Berinstein, N.L.1    Karkada, M.2    Morse, M.A.3    Nemunaitis, J.J.4    Chatta, G.5    Kaufman, H.6
  • 59
    • 69049089548 scopus 로고    scopus 로고
    • The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research
    • Cheever M.A., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15(September (17)):5323-5337.
    • (2009) Clin Cancer Res , vol.15 , Issue.SEPTEMBER 17 , pp. 5323-5337
    • Cheever, M.A.1    Allison, J.P.2    Ferris, A.S.3    Finn, O.J.4    Hastings, B.M.5    Hecht, T.T.6
  • 60
    • 84877945468 scopus 로고    scopus 로고
    • Immune system targeting by biodegradable nanoparticles for cancer vaccines
    • Silva J.M., Videira M., Gaspar R., Preat V., Florindo H.F. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 2013, 168(June (2)):179-199.
    • (2013) J Control Release , vol.168 , Issue.JUNE 2 , pp. 179-199
    • Silva, J.M.1    Videira, M.2    Gaspar, R.3    Preat, V.4    Florindo, H.F.5
  • 62
    • 84991035719 scopus 로고    scopus 로고
    • Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation
    • Vatsan R., Bross P., Liu K., Theoret M., De Claro A., Lu J., et al. Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation. J Immunother Cancer 2013, 1(1):5.
    • (2013) J Immunother Cancer , vol.1 , Issue.1 , pp. 5
    • Vatsan, R.1    Bross, P.2    Liu, K.3    Theoret, M.4    De Claro, A.5    Lu, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.